Sign In
Buy XBIO
$3.38
+0.0700 (+2.11%)
At Close: Jun 02, 2026
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
07:26pm, Tuesday, 12'th Aug 2025
Xenetic Biosciences (XBIO) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.83 per share a year ago.
Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 / Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
08:30am, Wednesday, 23'rd Jul 2025
Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date FRAMINGHAM, MA / ACCESS Newswire / July 23, 2
Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNess Company evaluating systemic recombinant human DNase I (DNase I) i
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
08:05am, Wednesday, 14'th May 2025
Strategic focus on exploratory investigator-initiated clinical studies with institutional partners Continued progress of DNase I development program towards IND and first-in-human study for treatment
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
09:15am, Wednesday, 09'th Apr 2025
- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (S
Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / March 26, 2025 / Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
08:05am, Wednesday, 19'th Mar 2025
Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers Strategic focus on exploratory investigator-initiated clinical studie
Data presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting Findings demonstrate that by degrading neutrophil extracellular traps (NETs), DNase I not o
FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
09:15am, Tuesday, 17'th Dec 2024
Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virginia for the advancement of
Company continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December 16, 2024 / Xenetic Biosciences, Inc.
Collaboration utilizes PeriNess' expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / AC
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
09:15am, Friday, 22'nd Nov 2024
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SIT
Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer Results bolster Company's rationale for incorporating DNas
